NYSE:PRME Prime Medicine (PRME) Stock Price, News & Analysis $1.76 -0.03 (-1.40%) As of 03:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Prime Medicine Stock (NYSE:PRME) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prime Medicine alerts:Sign Up Key Stats Today's Range$1.71▼$1.8050-Day Range$1.15▼$3.2952-Week Range$1.12▼$8.27Volume618,575 shsAverage Volume1.21 million shsMarket Capitalization$230.19 millionP/E RatioN/ADividend YieldN/APrice Target$13.38Consensus RatingBuy Company OverviewPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Read More… Prime Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScorePRME MarketRank™: Prime Medicine scored higher than 55% of companies evaluated by MarketBeat, and ranked 494th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingPrime Medicine has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrime Medicine has only been the subject of 3 research reports in the past 90 days.Read more about Prime Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prime Medicine are expected to grow in the coming year, from ($1.68) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prime Medicine is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prime Medicine is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrime Medicine has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PRME. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldPrime Medicine does not currently pay a dividend.Dividend GrowthPrime Medicine does not have a long track record of dividend growth.Read more about Prime Medicine's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for PRME. News and Social Media2.7 / 5News Sentiment0.88 News SentimentPrime Medicine has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Prime Medicine this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for PRME on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows3 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prime Medicine insiders have not sold or bought any company stock.Percentage Held by Insiders23.47% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prime Medicine's insider trading history. Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address PRME Stock News HeadlinesPrime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Buy" by BrokeragesApril 20, 2025 | americanbankingnews.comPrime Medicine Stock Price, Quotes and ForecastsApril 13, 2025 | benzinga.comTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.April 24, 2025 | Crypto 101 Media (Ad)Prime Medicine price target raised to $16 from $15 at ChardanMarch 20, 2025 | markets.businessinsider.comWhy Prime Medicine Stock Was Climbing Higher This WeekMarch 20, 2025 | fool.comPrime Medicine Advances AATD Program With Prime Editing For Potential Curative TreatmentMarch 20, 2025 | nasdaq.comWhy Prime Medicine Stock Is Soaring TodayMarch 19, 2025 | fool.comPrime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth PotentialMarch 19, 2025 | tipranks.comSee More Headlines PRME Stock Analysis - Frequently Asked Questions How have PRME shares performed this year? Prime Medicine's stock was trading at $2.92 on January 1st, 2025. Since then, PRME stock has decreased by 39.9% and is now trading at $1.7550. View the best growth stocks for 2025 here. How were Prime Medicine's earnings last quarter? Prime Medicine, Inc. (NYSE:PRME) posted its quarterly earnings results on Friday, March, 7th. The company reported ($1.65) EPS for the quarter. When did Prime Medicine IPO? Prime Medicine (PRME) raised $175 million in an initial public offering (IPO) on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share. Who are Prime Medicine's major shareholders? Prime Medicine's top institutional shareholders include Palumbo Wealth Management LLC (0.07%), Green Alpha Advisors LLC (0.06%) and Rhumbline Advisers (0.06%). Insiders that own company stock include Robert Nelsen and 2019 Gp LLC Gv. View institutional ownership trends. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prime Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prime Medicine investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Intel (INTC), NVIDIA (NVDA), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings3/07/2025Today4/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:PRME CIK1894562 Webprimemedicine.com Phone617-564-0013FaxN/AEmployees234Year FoundedN/APrice Target and Rating Average Stock Price Target$13.38 High Stock Price Target$18.00 Low Stock Price Target$10.00 Potential Upside/Downside+651.4%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-198,130,000.00 Net MarginsN/A Pretax Margin-27,406.12% Return on Equity-107.87% Return on Assets-74.97% Debt Debt-to-Equity RatioN/A Current Ratio6.50 Quick Ratio6.50 Sales & Book Value Annual Sales$2.98 million Price / Sales78.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book1.30Miscellaneous Outstanding Shares131,161,000Free Float100,378,000Market Cap$233.47 million OptionableOptionable Beta1.88 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NYSE:PRME) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.